For optimal viewing of our online annual please use Chrome or Firefox.
Delivering Transformational Medicines to Patients
2014 Annual Report
Rusty Cline participated in a clinical trial for a new immunotherapy from Bristol-Myers Squibb.
Our performance in 2014 across brands and geographies, continued
innovation and productivity in R&D, and investments in business development
opportunities reflect the strength and execution of our BioPharma strategy and
positions us well for 2015. By keeping patients at the center of everything we do,
we are working hard to develop innovative medicines that have the potential to
transform the lives of the people we serve.
Message from the Chief Executive Officer
"By every indication, Bristol-Myers Squibb is well positioned for continued success. We have the right products. We have the right plans. We have the right people."
Lamberto Andreotti, Chief Executive Officer
Message from the Chairman of the Board
"More than ever, we are making a meaningful difference in the lives of our patients."
James M. Cornelius, Chairman
Chief Operating Officer and CEO-Designate
"I am honored to have
the privilege to lead
this great company."
Giovanni Caforio, M.D.,
Chief Operating Officer and CEO-Designate
Business Highlights
"What we do - we focus on our customers’ needs, giving maximum priority
to accelerating pipeline development, delivering sales growth and continuing to
manage costs."
Our commercial and R&D organizations share a common purpose: to accelerate innovation in areas of high unmet medical need, and offer meaningful and differentiated improvements in the lives of patients.
Leading the Way in Immuno-Oncology
Despite continuing advances in cancer treatment, for most tumors, once the cancer spreads beyond the original tumor site, chances for long-term survival for most patients unfortunately have remained elusive - until recently.
A Look Toward the Future
The evolution of Bristol-Myers Squibb's R&D strategy, announced in late 2013, has focused on exploring disease areas of highest unmet medical need where the company can bring the greatest value to patients.
Research and Development Pipeline
In 2014, Bristol-Myers Squibb invested $4.5 billion in R&D, which included the discovery and development of new medicines for patients.
Our Corporate Responsibility
In communities around the world, Bristol-Myers Squibb is focused on its responsibilities as a corporate citizen, promoting health equity and improving health outcomes through its Foundation, expanding global access to health care through global policy initiatives, reducing its environmental footprint and enhancing employee safety and diversity to meet its sustainability goals.
